scholarly journals Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus

2016 ◽  
Vol 351 (4) ◽  
pp. 416-419 ◽  
Author(s):  
R. William Chong ◽  
Vijaya Vasudevan ◽  
Jeffrey Zuber ◽  
Solomon S. Solomon
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Therapeutic Effect ◽  
Positive Therapeutic Effect

Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)

2021 ◽  
Author(s):  
Rocío Barrios-Rodríguez ◽  
Esther García-Esquinas ◽  
Beatriz Pérez-Gómez ◽  
Gemma Castaño-Vinyals ◽  
Javier Llorca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Risk Score ◽  
Cancer Genetic

Metabonomic analysis of the therapeutic effect of Potentilla discolor in the treatment of type 2 diabetes mellitus

2014 ◽  
Vol 10 (11) ◽  
pp. 2898-2906 ◽  
Author(s):  
Yi Li ◽  
Jing-jing Li ◽  
Xiao-dong Wen ◽  
Rong Pan ◽  
Yi-sheng He ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Therapeutic Effect ◽  
Corosolic Acid

A plasma metabonomic approach was applied to investigate the effects of P. discolor and corosolic acid.

scholarly journals Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer

2020 ◽  
Vol 27 (9) ◽  
pp. 817-820
Author(s):  
Mohammad‐Ali Haghsheno ◽  
Jan Hammarsten ◽  
Ralph Peeker ◽  
Carl Johan Behre ◽  
Dan Mellström ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Detection Rate ◽  
Lower Detection

scholarly journals The Influence of Hyperglycemia on the Therapeutic Effect of Exercise on Glycemic Control in Patients With Type 2 Diabetes Mellitus

2013 ◽  
Vol 173 (19) ◽  
pp. 1834 ◽  
Author(s):  
Thomas P. J. Solomon ◽  
Steven K. Malin ◽  
Kristian Karstoft ◽  
Jacob M. Haus ◽  
John P. Kirwan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Therapeutic Effect

scholarly journals Exploring the Association Between Prostate Cancer Diagnosis per se and use of GnRH Agonists and Diabetes Control in Men with type 2 Diabetes Mellitus: A Nationwide, Population-Based Cohort Study

2021 ◽  
Author(s):  
E Lin ◽  
Hans Garmo ◽  
Mieke Hemelrijck ◽  
Jan Adolfsson ◽  
Pär Stattin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Population Based ◽  
Diabetes Control ◽  
Gnrh Agonists ◽  
Cancer Data

Abstract Background: Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM.Methods: Nationwide population-based cohort study in the Swedish National Diabetes Register and Prostate Cancer data Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. Worsening diabetes control was the primary outcome, defined as: 1) increase of HbA1c to 58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of antidiabetic drugs or switch to insulin; 4) combine all definitions above. Cox proportional hazards regression was used to analyze the association. Results: There were 5,714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free men with T2DM with similar baseline characteristics. Diabetes control was worse in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13-1.34) as well as compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39-1.80). Conclusion: Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The findings highlight the need to closely monitor diabetes control in men with T2DM and PCa starting GnRH agonists and to limit the duration of their use when possible.

Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus

2021 ◽  
pp. 113720
Author(s):  
Yu-Long He ◽  
Meng-Ting Chen ◽  
Ting Wang ◽  
Ming-Ming Zhang ◽  
Ying-Xia Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Therapeutic Effect
Sign in / Sign up

Export Citation Format

Share Document